Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title> <jats:p>The development of a vaccine against tuberculosis (TB), a disease caused by <jats:named-content content-type="genus-species">Mycobacterium tuberculosis</jats:named-content>, is urgently needed. The only currently available vaccine, <jats:named-content content-type="genus-species">M. bovis</jats:named-content> BCG, has variable efficacy. One approach in the global vaccine development effort is focused on boosting BCG using subunit vaccines. The identification of novel antigens for inclusion in subunit vaccines is a critical step in the TB vaccine development pathway. We selected four novel mycobacterial antigens recognized during the course of human infection. A replication-deficient chimpanzee adenovirus (ChAdOx1) was constructed to express each antigen individually, and these vectors were evaluated for protective efficacy in murine <jats:named-content content-type="genus-species">M. tuberculosis</jats:named-content> challenge experiments. One antigen, PPE15 (Rv1039c), conferred significant and reproducible protection when administered alone and as a boost to BCG vaccination. We identified immunodominant epitopes to define the protective immune responses using tetramers and intravascular staining. Lung parenchymal CD4<jats:sup>+</jats:sup> and CD8<jats:sup>+</jats:sup> CXCR3<jats:sup>+</jats:sup> KLRG1<jats:sup>−</jats:sup> T cells, previously associated with protection against <jats:named-content content-type="genus-species">M. tuberculosis</jats:named-content>, were enriched in the vaccinated groups compared to the control groups. Further work to evaluate the protective efficacy of PPE15 in more stringent preclinical animal models, together with the identification of further novel protective antigens using this selection strategy, is now merited.</jats:p>

Original publication




Journal article


Infection and Immunity


American Society for Microbiology

Publication Date





e00014 - 18